China Shineway Pharmaceutical Group Limited
CSWYF
$0.9398
$0.07378.51%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 117.56M | 118.13M | 144.08M | 145.33M | 146.66M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 117.56M | 118.13M | 144.08M | 145.33M | 146.66M |
| Cost of Revenue | 30.01M | 30.16M | 35.53M | 35.83M | 36.54M |
| Gross Profit | 87.55M | 87.97M | 108.55M | 109.49M | 110.12M |
| SG&A Expenses | 64.53M | 64.84M | 66.76M | 67.34M | 79.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 98.42M | 98.89M | 105.37M | 106.29M | 120.06M |
| Operating Income | 19.14M | 19.24M | 38.71M | 39.04M | 26.60M |
| Income Before Tax | 19.72M | 19.81M | 59.52M | 60.04M | 39.40M |
| Income Tax Expenses | 4.87M | 4.89M | 16.27M | 16.41M | 6.30M |
| Earnings from Continuing Operations | 14.85M | 14.92M | 43.26M | 43.63M | 33.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.85M | 14.92M | 43.26M | 43.63M | 33.10M |
| EBIT | 19.14M | 19.24M | 38.71M | 39.04M | 26.60M |
| EBITDA | 21.07M | 22.41M | 44.28M | 44.66M | 32.12M |
| EPS Basic | 0.02 | 0.02 | 0.06 | 0.06 | 0.04 |
| Normalized Basic EPS | 0.02 | 0.02 | 0.05 | 0.05 | 0.03 |
| EPS Diluted | 0.02 | 0.02 | 0.06 | 0.06 | 0.04 |
| Normalized Diluted EPS | 0.02 | 0.02 | 0.05 | 0.05 | 0.03 |
| Average Basic Shares Outstanding | 755.40M | 755.40M | 755.40M | 755.40M | 755.40M |
| Average Diluted Shares Outstanding | 755.40M | 755.40M | 755.40M | 755.40M | 755.40M |
| Dividend Per Share | 0.00 | 0.00 | 0.04 | 0.04 | 0.00 |
| Payout Ratio | 38.91% | 38.91% | 51.85% | 51.85% | 17.38% |